https://wiki.tradeville.ro/index.php?action=history&feed=atom&title=Otonomy%2C_Inc.Otonomy, Inc. - Revizia istoricului2026-05-09T17:05:33ZIstoricul versiunilor pentru această pagină din wikiMediaWiki 1.39.2https://wiki.tradeville.ro/index.php?title=Otonomy,_Inc.&diff=434581&oldid=prevAdmin: Pagină nouă: Pagina dedicata companiei Otonomy, Inc. listata cu simbolul US.OTIC ==Descriere companie== Otonomy, Inc. (http://www.otonomy.com/) is a biopharmaceutical company. The Company is focused on the development of therapeutics for neurotology. The Company pipeline includes OTIPRIO, OTIVIDEX, OTO-313, and OTO-413. OTIPRIO is a single-dose, physician-administered antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery fo...2024-09-18T18:19:33Z<p>Pagină nouă: Pagina dedicata companiei Otonomy, Inc. listata cu simbolul US.OTIC ==Descriere companie== Otonomy, Inc. (http://www.otonomy.com/) is a biopharmaceutical company. The Company is focused on the development of therapeutics for neurotology. The Company pipeline includes OTIPRIO, OTIVIDEX, OTO-313, and OTO-413. OTIPRIO is a single-dose, physician-administered antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery fo...</p>
<p><b>Pagină nouă</b></p><div>Pagina dedicata companiei Otonomy, Inc. listata cu simbolul US.OTIC<br />
<br />
==Descriere companie==<br />
Otonomy, Inc. (http://www.otonomy.com/) is a biopharmaceutical company. The Company is focused on the development of therapeutics for neurotology. The Company pipeline includes OTIPRIO, OTIVIDEX, OTO-313, and OTO-413. OTIPRIO is a single-dose, physician-administered antibacterial for the treatment of pediatric patients with bilateral otitis media with effusion undergoing TTP surgery for the treatment of patients with acute otitis externa (AOE). OTIVIDEX is a sustained-exposure formulation of the steroid dexamethasone in development for the treatment of Menieres disease. OTO-313 is a sustained-exposure formulation of gacyclidine, a potent and selective N-Methyl-D-Aspartate (NMDA) receptor antagonist, in development for the treatment of tinnitus. OTO-413 is a sustained-exposure formulation of brain-derived neurotrophic factor (BDNF) in development for the repair of cochlear synaptopathy, an underlying pathology in age-related and noise-induced hearing loss.<br />
<br />
==Grafic actiuni companie==<br />
<iframe key="tradeville" path="graficSimbol/US.OTIC" /><br />
<br />
==Ultimele stiri despre Otonomy, Inc. (US.OTIC)==<br />
<dynamicpagelist><br />
category=US.OTIC<br />
count=10<br />
order=descending<br />
addfirstcategorydate=false<br />
</dynamicpagelist><br />
<br />
[[Categorie:US.OTIC]][[Categorie:Stiri despre companii]]</div>Admin